Long-term treatment with rilzabrutinib in patients with immune
thrombocytopenia

J 2024

Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia

KUTER, David J, Jiří MAYER, Merlin EFRAIM, Lachezar H BOGDANOV, Ross BAKER et. al.

Základní údaje

Originální název

Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia

Autoři

KUTER, David J, Jiří MAYER (203 Česká republika, domácí), Merlin EFRAIM, Lachezar H BOGDANOV, Ross BAKER, Zane KAPLAN, Mamta GARG, A J Gerard JANSEN, Marek TRNENY, Philip Y CHOI, Vickie MCDONALD, Jaromir GUMULEC, Milan KOSTAL, Terry GERNSHEIMER, Waleed GHANIMA, Ahmed DAAK a Nichola COOPER

Vydání

Blood advances, AMSTERDAM, ELSEVIER, 2024, 2473-9529

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 7.500 v roce 2022

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1182/bloodadvances.2023012044

UT WoS

001206647600002

Klíčová slova anglicky

immune thrombocytopenia; rilzabrutinib

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 5. 6. 2024 09:01, Mgr. Tereza Miškechová

Anotace

V originále

Immune thrombocytopenia (ITP) is an autoimmune disease associated with autoantibodymediated platelet destruction and impaired platelet production, resulting in thrombocytopenia and a predisposition to bleeding. The ongoing, global phase 1/2 study showed that rilzabrutinib, a Bruton tyrosine kinase inhibitor specifically developed to treat autoimmune disorders, could be an efficacious and well-tolerated treatment for ITP. Clinical activity, durability of response, and safety were evaluated in 16 responding patients who continued rilzabrutinib 400 mg twice daily in the long-term extension (LTE) study. At LTE entry, the median platelet count was 87 x 10(9)/L in all patients, 68 x 10(9)/L in those who had rilzabrutinib monotherapy (n = 5), and 156 x 10(9)/L in patients who received concomitant ITP medication (thrombopoietin-receptor agonists and/or corticosteroids, n = 11). At a median duration of treatment of 478 days (range, 303-764), 11 of 16 patients (69%) continued to receive rilzabrutinib. A platelet count of >= 50 x 109/L was reported in 93% of patients for more than half of their monthly visits. The median percentage of LTE weeks with platelet counts >= 30 x 10(9)/L and >= 50 x 10(9)/L was 100% and 88%, respectively. Five patients discontinued concomitant ITP therapy and maintained median platelet counts of 106 x 10(9)/L at 3 to 6 months after stopping concomitant ITP therapy. Adverse events related to treatment were grade 1 or 2 and transient, with no bleeding, thrombotic, or serious adverse events. With continued rilzabrutinib treatment in the LTE, platelet responses were durable and stable over time with no new safety signals.

Citovat

KUTER, David J, Jiří MAYER, Merlin EFRAIM, Lachezar H BOGDANOV, Ross BAKER, Zane KAPLAN, Mamta GARG, A J Gerard JANSEN, Marek TRNENY, Philip Y CHOI, Vickie MCDONALD, Jaromir GUMULEC, Milan KOSTAL, Terry GERNSHEIMER, Waleed GHANIMA, Ahmed DAAK a Nichola COOPER. Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia. Blood advances. AMSTERDAM: ELSEVIER, 2024, roč. 8, č. 7, s. 1715-1724. ISSN 2473-9529. Dostupné z: https://dx.doi.org/10.1182/bloodadvances.2023012044.

@article{2407799,
   author = {Kuter, David J and Mayer, Jiří and Efraim, Merlin and Bogdanov, Lachezar H and Baker, Ross and Kaplan, Zane and Garg, Mamta and Jansen, A J Gerard and Trneny, Marek and Choi, Philip Y and Mcdonald, Vickie and Gumulec, Jaromir and Kostal, Milan and Gernsheimer, Terry and Ghanima, Waleed and Daak, Ahmed and Cooper, Nichola},
   article_location = {AMSTERDAM},
   article_number = {7},
   doi = {http://dx.doi.org/10.1182/bloodadvances.2023012044},
   keywords = {immune thrombocytopenia; rilzabrutinib},
   language = {eng},
   issn = {2473-9529},
   journal = {Blood advances},
   title = {Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia},
   url = {https://ashpublications.org/bloodadvances/article/8/7/1715/515037/Long-term-treatment-with-rilzabrutinib-in-patients},
   volume = {8},
   year = {2024}
}

TY  - JOUR
ID  - 2407799
AU  - Kuter, David J - Mayer, Jiří - Efraim, Merlin - Bogdanov, Lachezar H - Baker, Ross - Kaplan, Zane - Garg, Mamta - Jansen, A J Gerard - Trneny, Marek - Choi, Philip Y - Mcdonald, Vickie - Gumulec, Jaromir - Kostal, Milan - Gernsheimer, Terry - Ghanima, Waleed - Daak, Ahmed - Cooper, Nichola
PY  - 2024
TI  - Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia
JF  - Blood advances
VL  - 8
IS  - 7
SP  - 1715-1724
EP  - 1715-1724
PB  - ELSEVIER
SN  - 24739529
KW  - immune thrombocytopenia
KW  - rilzabrutinib
UR  - https://ashpublications.org/bloodadvances/article/8/7/1715/515037/Long-term-treatment-with-rilzabrutinib-in-patients
N2  - Immune thrombocytopenia (ITP) is an autoimmune disease associated with autoantibodymediated platelet destruction and impaired platelet production, resulting in thrombocytopenia and a predisposition to bleeding. The ongoing, global phase 1/2 study showed that rilzabrutinib, a Bruton tyrosine kinase inhibitor specifically developed to treat autoimmune disorders, could be an efficacious and well-tolerated treatment for ITP. Clinical activity, durability of response, and safety were evaluated in 16 responding patients who continued rilzabrutinib 400 mg twice daily in the long-term extension (LTE) study. At LTE entry, the median platelet count was 87 x 10(9)/L in all patients, 68 x 10(9)/L in those who had rilzabrutinib monotherapy (n = 5), and 156 x 10(9)/L in patients who received concomitant ITP medication (thrombopoietin-receptor agonists and/or corticosteroids, n = 11). At a median duration of treatment of 478 days (range, 303-764), 11 of 16 patients (69%) continued to receive rilzabrutinib. A platelet count of >= 50 x 109/L was reported in 93% of patients for more than half of their monthly visits. The median percentage of LTE weeks with platelet counts >= 30 x 10(9)/L and >= 50 x 10(9)/L was 100% and 88%, respectively. Five patients discontinued concomitant ITP therapy and maintained median platelet counts of 106 x 10(9)/L at 3 to 6 months after stopping concomitant ITP therapy. Adverse events related to treatment were grade 1 or 2 and transient, with no bleeding, thrombotic, or serious adverse events. With continued rilzabrutinib treatment in the LTE, platelet responses were durable and stable over time with no new safety signals.
ER  -

KUTER, David J, Jiří MAYER, Merlin EFRAIM, Lachezar H BOGDANOV, Ross BAKER, Zane KAPLAN, Mamta GARG, A J Gerard JANSEN, Marek TRNENY, Philip Y CHOI, Vickie MCDONALD, Jaromir GUMULEC, Milan KOSTAL, Terry GERNSHEIMER, Waleed GHANIMA, Ahmed DAAK a Nichola COOPER. Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia. \textit{Blood advances}. AMSTERDAM: ELSEVIER, 2024, roč.~8, č.~7, s.~1715-1724. ISSN~2473-9529. Dostupné z: https://dx.doi.org/10.1182/bloodadvances.2023012044.

Podrobný výpis o publikaci